Amgen Inc (AMGN)

pos +1.68
Today's Range: 148.63 - 150.75 | AMGN Avg Daily Volume: 2,800,500
Last Update: 06/29/16 - 3:59 PM EDT
Volume: 3,766,311
YTD Performance: -8.57%
Open: $149.17
Previous Close: $148.42
52 Week Range: $130.09 - $181.81
Oustanding Shares: 751,217,078
Market Cap: 108,610,965,137
6-Month Chart
TheStreet Ratings Grade for AMGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 4 4 4 4
Moderate Buy 2 2 2 2
Hold 9 9 9 9
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.30 2.30 2.30 2.30
Latest Dividend: 1.00
Latest Dividend Yield: 2.77%
Dividend Ex-Date: 05/13/16
Price Earnings Ratio: 13.42
Price Earnings Comparisons:
AMGN Sector Avg. S&P 500
13.42 15.30 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
0.03% -6.08% 50.44%
Revenue 8.00 0.20 0.08
Net Income 34.50 0.60 0.17
EPS 35.20 0.60 0.18
Earnings for AMGN:
Revenue 21.66B
Average Earnings Estimates
Qtr (06/16) Qtr (09/16) FY (12/16) FY (12/17)
Average Estimate $2.74 $2.77 $11.16 $12.06
Number of Analysts 10 9 12 12
High Estimate $2.97 $3.19 $12.21 $13.54
Low Estimate $2.60 $2.65 $10.80 $11.16
Prior Year $2.57 $2.72 $10.38 $11.16
Growth Rate (Year over Year) 6.77% 1.96% 7.51% 8.03%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Large biotech stocks are still at their cheapest valuations since 2011.

Is Amgen Firming Up? Real Money Pro($)

A fresh rally leg could be on the way if AMGN can remain above the $152 area in the near term. 
Keep cash on hand and be ready for oportunities as they arise.
I prefer a bullish synthetic call.
But there is no guarantee that it will fully play out.
It is hard to see much growth in the market overall, until earnings growth returns.
The S&P 500 is testing the neckline of a head-and-shoulders pattern.

Intermediate Trade: Amgen Real Money Pro($)

The cream of the biotech crop seems to have found a floor after a rough set of earnings.
And it's hard to get excited about the second quarter, too.
We also look at Amgen and the biotech index.

Columnist Conversations

As of 10:19 PM the three major index futures were all slightly positive. It is so close to neutral that anythi...
Travelers is working on an impressive breakout today.  The stock is up just over 2.1% as it extends the rebou...
There is just not much to get excited about when looking at individual stock charts. I scanned about 80 diffe...
General Mills (GIS) surprised investors with a much better than expected 4th quarter today. Revenues were bett...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.